

SARS-CoV-2 (COVID-19) Spike-ACE2 Binding / Neutralization Assay Kit

Cat. No. GTX536401

Applications	Neutralizing/Inhibition
Reactivity	SARS Coronavirus 2

[References \(1 \)](#)

Package

96 test

PRODUCT

Summary The GeneTex SARS-CoV-2 (COVID-19) Spike-ACE2 Binding / Neutralization Assay Kit is an in vitro assay for qualitative SARS-CoV-2 neutralization reagent screening. The kit includes the recombinant RBD proteins of the wildtype (WT) strain and five major WHO-designated variants of concern (i.e., Alpha, Beta, Gamma, Delta, and Kappa) for strain-specific neutralization analysis.

Applications


Application Note

The suitable sample types include but not limit to purified antibodies and serum. The suggested sample loading amount is 50 μ l per well. Please see the protocol for detailed procedure.

Properties

Preservative	0.05% ProClin 300
Storage	The entire kit can be stored at 2-8°C for up to 6 months.
Conjugation	Horseradish peroxidase(HRP)
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.	
Note	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

DATA IMAGES



GTX536401 Neutralizing/Inhibition Image

Inhibition analysis of SARS-CoV-2 (COVID-19) spike neutralizing control antibody using SARS-CoV-2 (COVID-19) Spike-ACE2 Binding / Neutralization Assay Kit (GTX536401).



For full product information, images and publications, please visit our [website](#).

Date 2026 / 02 / 05 Page 1 of 2

	RBD WT	RBD Alpha	RBD Beta	RBD Gamma	RBD Delta	RBD Kappa
Average (%)	99.7	94.1	108.3	98.2	104.7	99.9
Range (%)	87-115	79-110	100-116	93-107	91-120	93-112

GTX536401 Image

The recovery of SARS-CoV-2 (COVID-19) Spike-ACE2 Binding / Neutralization Assay Kit (GTX536401) was determined by spiking a spike neutralizing control antibody in human serum.

**GTX536401 Image**

For full product information, images and publications, please visit our [website](#).

Date 2026 / 02 / 05 Page 2 of 2